RT Journal Article SR Electronic T1 Long-term Results of Preoperative 5-Fluorouracil-Oxaliplatin Chemoradiation Therapy in Locally Advanced Rectal Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 725 OP 730 VO 33 IS 2 A1 ELISA FONTANA A1 FRANCESCA PUCCI A1 ROBERTA CAMISA A1 SIMONA BUI A1 SALVATORE GALDY A1 FRANCESCO LEONARDI A1 FRANCESCA VIRGINIA NEGRI A1 ELISA ANSELMI A1 PIER LUIGI LOSARDO A1 LUIGI RONCORONI A1 PAOLO DELL'ABATE A1 PELLEGRINO CRAFA A1 STEFANO CASCINU A1 ANDREA ARDIZZONI YR 2013 UL http://ar.iiarjournals.org/content/33/2/725.abstract AB Aim: To evaluate the activity, safety and long-term survival of patients after preoperative oxaliplatin and 5-fluorouracil chemoradiation therapy in locally advanced rectal cancer (LARC). Patients and Methods: Patients with resectable, T3-4 and/or nodal involvement rectal adenocarcinoma were treated with oxaliplatin 60 mg/m2 weekly and 5-fluorouracil 200 mg/m2/d infused continuously for five days, over a period of five weeks, and radiotherapy (45 Gy/25 fractions). The primary end-point was pathological complete response (ypCR). Safety, overall survival (OS) and relapse-free survival (RFS) were secondary end-points. Results: Sixty-six patients were treated. Grade 1-2 diarrhea was the most common adverse event. The ypCR rate was 16.7% (95% confidence interval=7.7-25.7%). After a median follow-up of 73.5 months, 23 patients (34.8%) had experienced relapse. Five-year actuarial RFS and OS rates were 64% and 73%, respectively. Five-year actuarial RFS was 91.7% in the ypCR group versus 57.8% in non-ypCR cases. Conclusion: Long-term local control and survival after this very well-tolerated regimen appear encouraging.